Thank you, Mr. Chair.
Thank you, both, for coming. It was very valuable testimony, and I'll probably by contacting you both off-line regarding some more information on this.
Mr. Clark, thank you for your comment about the claims from industry that, by lowering our prices, we will decrease R and D and decrease access to new medications. I have had to wrestle with that argument from many stakeholders. You've said there is really no evidence to support this. Is that correct? Could you elaborate on that?